Compare Abeona Therapeutics Inc (ABEO) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Virgin Galactic Holdings, Inc. trades at $2.6 (market cap $330.34M). The key difference: Abeona Therapeutics Inc and Virgin Galactic Holdings, Inc. are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | SPCE | |
|---|---|---|
Market Cap | $373.32M | $330.34M |
Sector | Health | Industrials |
52-Week High | $7.23 | $7.52 |
52-Week Low | $4.17 | $2.17 |
Enterprise Value | $228.22M | $430.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Virgin Galactic (SPCE) trades at $2.57, down 4.81% today, reflecting persistent bearish technical signals and weak fundamentals. The company continues to report significant losses, with a net income margin of -19,781.3% in 2025 and negative cash flow from operations. Recent news highlights volatility tied to SpaceX IPO developments, with SPCE shares experiencing sharp swings. Analyst consensus is mixed, with 29% buy, 41% hold, and 29% sell ratings, indicating cautious sentiment amid ongoing financial challenges.
The outlook remains highly speculative, with investment opportunity hinging on future commercial spaceflight success, but risks are substantial. High cash burn, lack of profitability, and intense competition threaten shareholder value. Without near-term revenue growth or path to profitability, the stock faces significant downside risk despite trading near historical lows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
